Ajanta Pharma informs about disclosure of material impact of COVID-19

11 Jun 2020 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CMDl/CIR/P/2020/84 dated 20th May 2020, Ajanta Pharma has informed that it has enclosed the disclosure of material impact of COVID 19 pandemic on listed companies.

The above information is a part of company’s filings submitted to BSE.


Ajanta Pharma Share Price

2706.15 9.75 (0.36%)
28-Jan-2026 11:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1617.05
Dr. Reddys Lab 1221.75
Cipla 1318.35
Zydus Lifesciences 890.85
Lupin 2122.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×